Study: Pozelimab Shows Positive Results in the Treatment of Paroxysmal Nocturnal Hemoglobinuria
source: pixabay.com

Study: Pozelimab Shows Positive Results in the Treatment of Paroxysmal Nocturnal Hemoglobinuria

  Regeneron Pharmaceuticals has recently announced the results of Phase 2 of their study of pozelimab, which is an experimental treatment for paroxysmal nocturnal hemoglobinuria. Current therapies for this condition…

Continue Reading Study: Pozelimab Shows Positive Results in the Treatment of Paroxysmal Nocturnal Hemoglobinuria
Company Announces Completion of Safety Review for Initial Cohort in Cholangiocarcinoma Trial
source: pixabay.com

Company Announces Completion of Safety Review for Initial Cohort in Cholangiocarcinoma Trial

According to a story from globenewswire.com, the biopharmaceutical company Lexicon Pharmaceuticals has recently announced that it has completed its safety review of the initial cohort for its phase 2 clinical…

Continue Reading Company Announces Completion of Safety Review for Initial Cohort in Cholangiocarcinoma Trial

Experimental Myelodysplastic Syndrome Treatment Receives Breakthrough Therapy Designation

  A drug created by Agios Pharmaceuticals, TIBSOVO, was recently granted the Breakthrough Therapy designation by the FDA for the treatment of relapsed or refractory myelodysplastic syndrome (MDS) with an…

Continue Reading Experimental Myelodysplastic Syndrome Treatment Receives Breakthrough Therapy Designation
Researchers Identify Method to Help Detect Pulmonary Arterial Hypertension in Systemic Sclerosis Patients
source: pixabay.com

Researchers Identify Method to Help Detect Pulmonary Arterial Hypertension in Systemic Sclerosis Patients

According to a story from Pulmonary Hypertension News, a recent study has determined that cardiopulmonary exercise testing can be an effective method to help identify systemic sclerosis patients that are…

Continue Reading Researchers Identify Method to Help Detect Pulmonary Arterial Hypertension in Systemic Sclerosis Patients
Trial Application for Experimental Cannabinoid Epidermolysis Bullosa Treatment Gains Approval
source: pixabay.com

Trial Application for Experimental Cannabinoid Epidermolysis Bullosa Treatment Gains Approval

According to a story from prnewswire.com, the biopharmaceutical company InMed Pharmaceuticals, Inc. has recently announced that that company's Clinical Trial Application has been approved in the Netherlands. This approval will…

Continue Reading Trial Application for Experimental Cannabinoid Epidermolysis Bullosa Treatment Gains Approval